Personalizing chemotherapy dosing using pharmacological methods Jai N. PatelApostolos Papachristos Review Article 23 August 2015 Pages: 879 - 896
Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial Robert J. MorganTimothy W. SynoldEdward M. Newman Original Article 11 September 2015 Pages: 897 - 907
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89) Vered Shkalim-ZemerShifra AshIan J. Cohen Original Article 13 September 2015 Pages: 909 - 916
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors Kelong HanJin Y. JinNageshwar R. Budha Original Article 13 September 2015 Pages: 917 - 924
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer Johanna C. BendellLee S. RosenManish R. Patel Original Article Open access 14 September 2015 Pages: 925 - 932
Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer Hyo-Sun LeeYun-Gyoo LeeSeung-Sei Lee Original Article 15 September 2015 Pages: 933 - 937
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA) Benoit YouGilles SallesGilles Freyer Original Article 21 September 2015 Pages: 939 - 948
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC) Daniel J. AllendorfRodolfo E. BordoniFrancisco Robert Original Article 22 September 2015 Pages: 949 - 955
Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients Ben F. BultenHein J. VerberneLioe-Fee de Geus-Oei Original Article Open access 23 September 2015 Pages: 957 - 967
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma N. YamazakiH. UharaT. Tokudome Original Article Open access 25 September 2015 Pages: 969 - 975
Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition Linna ZhangKathleen ScorsonePeter E. Zage Original Article 25 September 2015 Pages: 977 - 987
Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients Haruka ShinkeSatohiro MasudaKazuo Matsubara Original Article 25 September 2015 Pages: 989 - 996
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma N. YamazakiY. KiyoharaT. Tokudome Original Article Open access 26 September 2015 Pages: 997 - 1004
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary Sameh MikhailMaryam B. LustbergTanios Bekaii-Saab Original Article 28 September 2015 Pages: 1005 - 1012
Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype Manu LopusGreg SmiyunMary Ann Jordan Original Article 28 September 2015 Pages: 1013 - 1024
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors Anthony W. TolcherPatricia LoRussoLee S. Rosen Original Article 29 September 2015 Pages: 1025 - 1032
Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters Zahra AjgalNicolas ChapuisJerome Alexandre Original Article 29 September 2015 Pages: 1033 - 1039
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study Anthony W. TolcherPatricia LoRussoLee S. Rosen Original Article 01 October 2015 Pages: 1041 - 1049
Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function Antoinette R. TanJohn SarantopoulosSanjay Goel Original Article Open access 03 October 2015 Pages: 1051 - 1061
A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC) Hidenori MizugakiNoboru YamamotoTomohide Tamura Original Article Open access 03 October 2015 Pages: 1063 - 1072
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma Andrew GabrielsonAnteneh A. TesfayeAiwu Ruth He Original Article Open access 08 October 2015 Pages: 1073 - 1079
Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations Christian QueckenbergV. ErlinghagenU. Fuhr Clinical Trial Report 05 August 2015 Pages: 1081 - 1091
Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors Vijaya L. DamarajuMichelle KuzmaMichael B. Sawyer Short Communication 02 September 2015 Pages: 1093 - 1098
Erratum to: Inhibition of ovarian cancer cell growth by a novel TAK1 inhibitor LYTAK1 Liu WeiLiu YingYin Chunxia Erratum 08 October 2015 Pages: 1099 - 1099